文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SORENTO临床试验方法学:一项评估高暴露奥曲肽皮下储库(CAM2029)在胃肠胰神经内分泌肿瘤患者中疗效与安全性的前瞻性、随机、活性对照3期试验

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
PubMed 文献 · Trials · 2024-01-16

SORENTO是一项前瞻性、多中心、随机、活性对照、开放标签3期试验,旨在约300例不可切除/转移性高分化胃肠胰神经内分泌肿瘤患者中证明每2周20 mg奥曲肽皮下储库(CAM2029)相比研究者选择的标准化疗生长抑素受体配体(奥曲肽长效释放30 mg或兰瑞肽ATG 120 mg每4周)在无进展生存期方面的优效性。主要分析将在194例确认的PFS事件后开展。

要点

  • SORENTO试验比较每2周20 mg CAM2029与研究者选择的标准化疗SRL在GEP-NET患者中的PFS优效性。
  • 主要终点PFS由盲态独立审查委员会(BIRC)按RECIST 1.1评估,计划在194例确认事件后分析。
  • 疾病进展后患者可进入开放标签扩展期,每周一次给药以研究更高频率给药的效果。

核心结论

  • SORENTO是首个采用头对头优效性设计研究CAM2029对比标准化疗SRL疗效的试验,预期为首个研究高暴露SRL增加给药频率疗效的试验;纳入高分化3级NET患者可能为该罕见研究人群阐明治疗策略。

研究设计与样本

  • 前瞻性、多中心、随机、活性对照、开放标签3期试验,计划纳入约300例不可切除/转移性高分化GEP-NET患者,随机接受每2周20 mg CAM2029或研究者选择的标准化疗SRL(奥曲肽LAR 30 mg或兰瑞肽ATG 120 mg每4周)。

主要发现

  • 主要终点为经BIRC按RECIST 1.1评估的PFS,主要分析在194例确认的PFS事件后进行;疾病进展后可进入开放标签扩展期接受每周一次给药;总生存随访在主要分析后最多2年结束。

关键数值与推荐

  • 试验组:CAM2029 20 mg每2周一次;对照组:奥曲肽LAR 30 mg每4周一次或兰瑞肽ATG 120 mg每4周一次(研究者选择);主要分析触发点:194例确认的PFS事件;总生存随访结束时间:主要分析后最多2年。

临床怎么用

  • 作者认为该试验将评估CAM2029对比标准化疗SRL的疗效与耐受性,并纳入高分化3级NET患者以探索该罕见研究人群的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) requires initiation of first-generation somatostatin receptor ligand (SRL) therapy, octreotide and lanreotide, which provide safe and efficacious tumour/symptom control in most patients. However, disease progression can occur with SoC SRL treatment and the optimal dose response of SRL remains unknown. Octreotide subcutaneous depot (CAM2029) is a novel, long-acting, high-exposure formulation that has shown greater bioavailability and improved administration than octreotide long-acting release (LAR) with a well-tolerated safety profile. Retrospective data have highlighted a potential benefit of high-exposure SRL for improved disease control in patients who did not adequately respond to the current SoC SRL treatment. This trial will investigate the efficacy and tolerability of CAM2029 compared to the current SoC, including octreotide LAR and lanreotide autogel (ATG). METHODS: SORENTO is a prospective, multicentre, randomised, active-controlled, open-label phase 3 trial aiming to demonstrate superiority of treatment with 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W) compared to treatment with the Investigator's choice of SRL therapy at standard doses for tumour control (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W]) as assessed by progression-free survival (PFS) in approximately 300 patients with unresectable/metastatic and well-differentiated GEP-NET. Upon confirmation of disease progression (determined by a Blinded Independent Review Committee [BIRC] and defined as per RECIST 1.1), patients may enter an open-label extension treatment period with once weekly dosing, to investigate the effects of higher frequency dosing. Overall survival follow-up will end a maximum of 2 years after primary analysis. The primary endpoint will be analysed after 194 confirmed PFS events. DISCUSSION: This is the first trial investigating the efficacy of CAM2029 versus SoC SRL therapy using a head-to-head, superiority trial design. It is expected to be the first trial to investigate the efficacy of increased dosing frequency of a high-exposure SRL. A BIRC will limit bias and measurement variability and ensure high-quality efficacy data. Additionally, inclusion of patients with well-differentiated Grade 3 NET may elucidate treatment strategies for this rarely investigated patient population. TRIAL REGISTRATION: ClinicalTrials.gov NCT05050942. Registered on 21st September 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Singh S, Ferone D, Capdevila J, et al. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024. PMID: 38229199. doi:10.1186/s13063-023-07834-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。